Maplight Therapeutics (NASDAQ:MPLT) Upgraded by Wall Street Zen to Hold Rating

Maplight Therapeutics (NASDAQ:MPLT) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other analysts have also recently weighed in on the stock. Jefferies Financial Group initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $32.00 price objective on the stock. Leerink Partners assumed coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued an “outperform” rating and a $30.00 target price on the stock. Morgan Stanley began coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set an “overweight” rating and a $34.00 price target on the stock. Leerink Partnrs upgraded shares of Maplight Therapeutics to a “strong-buy” rating in a research note on Friday, November 21st. Finally, Zacks Research raised Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $31.00.

Maplight Therapeutics Stock Up 3.1%

Shares of NASDAQ MPLT opened at $20.55 on Friday. Maplight Therapeutics has a 1 year low of $12.24 and a 1 year high of $21.55.

Maplight Therapeutics (NASDAQ:MPLT) last issued its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.